Venus Remedies Limited
NSE: VENUSREM · Pharmaceuticals · sector
₹1,461.80NSE close 2026-10-26
Key numbers
Market cap₹1,954 cr
Price₹1,461.80
52w high / low₹2,044 / ₹432
P/E16.8xSector median 27.9x
P/B2.9xSector median 2.9x
Book value₹496.4
Dividend yield–Sector median 0.48%
ROE19.0%Sector median 11.7%
ROCE22.8%Sector median 12.3%
OPM20.5%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA11.1xSector median 18.6x
Interest cover5,054.3x
Current ratio2.44x
Sales growth 3y+11.5%Sector median +9.6%
Profit growth 3y+57.0%Sector median +13.3%
PEG0.29x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹103 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Borrowings fell in each of the last 3 years (₹42 cr → ₹0 cr).
- Operating profit covered interest 5,054.3x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 0 of the last 5 years.
- Revenue was higher than a year earlier in 4 of the last 4 quarters.
- Other income was 10% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹1,461.80 on 2026-10-26: -28.5% from the 52-week high, +238.3% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹1,867.80 · low ₹286.85
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 167 | 177 | 195 | 132 | 193 | 180 | 259 | 179 |
| EBITDA | 5 | 28 | 29 | 10 | 31 | 38 | 63 | 34 |
| OPM % | 2.9% | 16.0% | 14.9% | 7.7% | 16.1% | 20.8% | 24.4% | 19.1% |
| Other income | 11 | 2 | 7 | 9 | 2 | 3 | 5 | 3 |
| Net profit | 4 | 20 | 21 | 10 | 20 | 26 | 47 | 23 |
| EPS (₹) | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 | 19.14 | 35.53 | 17.18 |
| Revenue YoY | +15.1% | +1.9% | +33.0% | +35.6% | ||||
| Profit YoY | +471.9% | +30.5% | +126.1% | +139.3% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 599 | 556 | 601 | 648 | 770 | 811 |
| EBITDA | 62 | 60 | 60 | 73 | 147 | 166 |
| Net profit | 41 | 27 | 27 | 45 | 103 | 116 |
| EPS (₹) | 30.86 | 19.88 | 21.31 | 33.90 | 76.89 | 86.91 |
| Revenue growth | -7.2% | +8.3% | +7.7% | +18.8% | +20.9% | |
| Profit growth | -34.7% | +2.4% | +66.5% | +126.8% | +116.3% | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +11.5% | +7.0% | +20.9% |
| Net profit | +57.0% | +10.7% | +116.3% |
| EPS | +57.0% | +9.0% | – |
| Share price | – | +109.5% (2y) | +232.4% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 460 | 488 | 561 | 664 |
| Borrowings | – | 42 | 41 | 2 | 0 |
| Cash & equivalents | – | 74 | 87 | 164 | 103 |
| Total assets | – | 601 | 627 | 716 | 854 |
| Fixed assets | – | 137 | 133 | 125 | 125 |
| Capital work in progress | – | 26 | 21 | 26 | 51 |
| Investments | – | 0 | 0 | 0 | 164 |
| Receivables | – | 77 | 80 | 112 | 103 |
| Inventory | – | 120 | 122 | 100 | 129 |
| Payables | – | 51 | 44 | 92 | 113 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 41 | 37 | 37 | 86 | 156 |
| Cash from investing | -17 | -51 | -7 | -76 | -182 |
| Cash from financing | -9 | -1 | -1 | -1 | -3 |
| Capex | 14 | 8 | 14 | 18 | 38 |
| Free cash flow | 27 | 29 | 24 | 68 | 118 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 5.8% | 5.6% | 8.1% | 15.5% |
| ROCE % | – | 7.6% | 8.5% | 12.8% | 20.2% |
| Debtor days | – | 50 | 49 | 63 | 49 |
| Inventory days | – | 132 | 125 | 97 | 122 |
| Payable days | – | 56 | 45 | 89 | 107 |
| Cash conversion cycle (days) | – | 126 | 129 | 71 | 64 |
| Working capital days | – | 158 | 170 | 178 | 111 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 41.76% |
| FIIs | 3.14% |
| DIIs | 0.74% |
| of which Mutual funds | 0.00% |
| Public (non-institutions) | 54.36% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% | 41.76% |
| Promoter group | % |
|---|---|
| Sunev Pharma Solutions Pvt Ltd | 17.21% |
| Pawan Chaudhary | 12.82% |
| Manu Chaudhary | 11.73% |
| Peeyush Jain | 0.00% |
| Akshansh Chaudhary | 0.00% |
| Ashutosh Jain | 0.00% |
| Saransh Chaudhary | 0.00% |
| Aditi K Chaudhary | 0.00% |
| Ekta Thakur | 0.00% |
| Monica Jain | 0.00% |
| Alka Jain | 0.00% |
| Spine Software Systems Pvt Lt | 0.00% |
| Tark AI Pvt Ltd | 0.00% |
| Radha Luxmi Investments | 0.00% |
| Plea Charitable Trust | 0.00% |
| Public holders above 1% | % |
|---|---|
| Tikri Partners LLP | 1.97% |
| Rajni Tarun Jain | 1.42% |
| Acadian Emerging Markets Micro-cap Equity Master Fund | 1.10% |
| Nisarg Ajaykumar Vakharia | 1.05% |
| Investor Education and Protection Fund Authority Ministry of Corporate Affairs | 1.00% |
22,968 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| VENUSREM | ₹1,954 cr | 16.8x | 2.9x | 19.0% | 22.8% | 20.5% | +11.5% | – |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-08-07 | Dividend | Dividend - Rs 10 Per Share |
| 2024-09-13 | Other | Annual General Meeting |
| 2023-08-17 | Other | Annual General Meeting |
| 2022-08-11 | Other | Annual General Meeting |
| 2021-09-09 | Other | Annual General Meeting |
| 2020-11-24 | Other | Annual General Meeting |
| 2019-09-20 | Other | Annual General Meeting |
| 2018-09-14 | Other | Annual General Meeting |
| 2017-09-21 | Other | Annual General Meeting |
| 2016-09-20 | Other | Annual General Meeting |
| 2015-08-17 | Other | Annual General Meeting |
| 2014-12-19 | Other | Annual General Meeting |
| 2013-09-23 | Dividend | Annual General Meeting / Dividend - Rs 3/- Per Share |
| 2012-09-20 | Dividend | Annual General Meeting / Dividend Rs. 3/- Per Share |
| 2011-09-22 | Dividend | Annual General Meeting And Dividend Rs.3/- Per Share |
| 2010-09-23 | Dividend | Annual General Meeting And Dividend Rs.3/- Per Share |
| 2009-09-17 | Other | Agm/Div-Rs.3/- Per Share |
| 2008-09-12 | Dividend | Agm/Dividend - 40% |
| 2007-09-18 | Dividend | Agm/Dividend-30% |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | VENUSREM |
| BSE code | 526953 |
| ISIN | INE411B01019 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-22 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.